Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular ...

Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

As a lecturer and clinical instructor in vision therapy and pediatrics, it is important to have a literature base for what I am teaching. My top 10 favorite vision therapy books provide that evidence ...

Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using ...

The release noted that brepocitinib demonstrated consistent benefits in preventing treatment failure across key subgroups, ...

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future ...

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier ...

From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry. Want more ...

Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness. Alcon has received FDA approval for apraclonidine ophthalmic solution 0.125% (Brytly) redness relief ...